Finny logo
Finny logo
Dibs:
Dibs:
0

Sorrento Therapeutics (SRNE) stock: what's the sentiment now?

4:57 am ET, 20 Aug 2018

Sorrento Therapeutics, Inc. (SRNE) shares are trading at 5.35.  The stock is down 29% since mid-July.  What's driving SRNE stock price? What's SRNE stock price forecast coming  into the earnings season?

First of all, let's note that healthcare and biotech stocks have been a subject to a broad selloff, some more than others. The SPDR S&P Biotech ETF (XBI) has declined more than the major indexes. 

The bulls say this is a great opportunity to buy Sorrento, citing a reasonable price for a solid, growth stock.  Among the near-term catalysts that can boost the stock value, analysts note great strategic partnerships and a strong pipeline.  Many traders are betting that Sorrento Therapeutics will become a key player in the immuno-oncology (I/O) space.

The bears are skeptical about the convertible debt that the company incurred, as well as less attractive financing deals.  J Capital Research asserts that the financing deals have benefited a select group of investors who are close to the CEO. 

What is the sentiment towards the SRNE stock? Our technical analysis shows that:

  • The stock short-term sentiment (next 30 days) is trending negative;
  • The mid-term sentiment (3-6 months) is trending negative;
  • The long-term sentiment (9-12 months) is trending negative. 

Over the last month, Sorrento Therapeutics (SRNE) returned -23.19%.

Sorrento Therapeutics (SRNE) short share of float is 16.27%. The stock is much more frequently shorted than the average industry, sector or S&P 500 stock.

Sorrento Therapeutics (SRNE) average analyst price target ($25.00) is 371.7% above its current price ($5.30).

For the latest price and information on Sorrento Therapeutics, please visit Finstead and search for "SRNE price" or "SRNE news".

Sorrento Therapeutics: Will It Bounce Back?

12:24 pm ET, 30 Mar 2018

Sorrento Therapeutics (NASDAQ: SRNE) stock was up over 10% in yesterday’s trading

Sorrento is a biopharma company that develops therapies to efficiently manage and cure malignant cancers. It uses a multimodal approach to fight cancer, which has been made possible through its comprehensive immuno-oncology platforms.

Earlier this year, Sorrento Therapeutics witnessed a huge sell-off. This occurred after ZTlido's approval.  

ZTlido is used for treating patients with post-herpetic neuralgia (i.e., post-shingles pain).  ZTlido has an advantage over other patch treatments in that it has better adhesion properties. It’s also a non-opioid.

Profit skimming and dilution risks are the main reasons behind this sell-off. 

The commercialization plan for ZTlido can lead to a sharp bounce-back of Sorrento's shares.

The company aims to launch Phase 1 of the clinical stage immuno-cellular therapies in multiple myeloma in partnership with Celularity.  Its dedication towards life-enhancing therapies for cancer patients has been evident from its effort to develop a first-in-class non-opioid pain management small molecule in Resiniferatoxin and ZTlido.

What is the stock price prediction (forecast) for Sorrento?  Per Finstead Research, the stock has an average price target of $22, which is much higher than its current price ($5.05).

Sorrento Therapeutics has negative valuation ratios which indicates that the company is not profitable, so trading its shares is highly speculative.


Sorrento Therapeutics, Inc. (SRNE) Stock Guide

Updated at: 3:23 pm ET, 18 Sep 2020

Before we start: if you're looking for SRNE stock price, you can quickly find it out by visiting Finny and typing "SRNE quote". If you're looking for a quick scoop on SRNE stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "SRNE". You'll get all this info in one place. Or you can just type "SRNE news" to get the latest stock news.

Looking to buy or sell Sorrento Therapeutics, Inc. (SRNE)? Interested in getting the full scoop on SRNE, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this SRNE stock guide, we'll address key questions about SRNE, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are SRNE earnings?
2. What is SRNE stock forecast (i.e., prediction)?
3. SRNE buy or sell? What is SRNE Finny Score?
4. What are the reasons to buy SRNE? Why should I buy SRNE stock?
5. What are the reasons to sell SRNE? Why should I sell SRNE stock?
6. What are SRNE key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are SRNE earnings?

SRNE trailing 12-month earnings per share (EPS) is -$1.64.

Analyst Predictions

2. What is SRNE stock forecast (i.e., prediction)?

Based on SRNE analyst price targets, SRNE stock forecast is $24.00 (for a year from now). That means the average analyst price target for SRNE stock is $24.00. The prediction is based on 2 analyst estimates.

The low price target for SRNE is $21.00, while the high price target is $30.00.

SRNE analyst rating is Buy.

Analysis

3. SRNE buy or sell? What is SRNE Finny Score?

#{finnyScore:73}Our quantitative analysis shows 8 reasons to buy and 3 reasons to sell SRNE, resulting in Finny Score of 73.

4. What are the reasons to buy SRNE? Why should I buy SRNE stock?

Here are the reasons to buy SRNE stock:

5. What are the reasons to sell SRNE? Why should I sell SRNE stock?

Let's look at the reasons to sell SRNE stock (i.e., the bear case):

Key Stats

6. What are SRNE key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for SRNE:

Metrics SRNE
Price $8.08
Average Price Target / Upside $24.00 / 197.03%
Average Analyst Rating Buy
Forward Dividend Yield 0.00%
Industry Biotechnology
Sector Healthcare
Number of Employees 162
Market Cap $2.64B
Forward P/E Ratio 2.94
Price/Book Ratio 74.38
Revenue (TTM) $35.54M
YoY Quarterly Revenue Growth 39.10%
Profit Margin 0.00%

If you liked this analysis, check out Stock Guides for other stocks.

Follow Us